COMMUNIQUÉS West-GlobeNewswire

Microbot Medical Successfully Transitions to Commercial Operations as It Records Revenue Resulting from Its Limited Market Release During the First Quarter of 2026
14/05/2026
Recent transition to the Full Market Release has already resulted in increased revenue for the current Q2, which has already exceeded Q1 revenue, as utilization and adoption of the LIBERTY System accelerates across [...]
Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment
14/05/2026
First-of-its-kind partnership expands NeuroStar platform capabilities with advanced visualization technology designed to address evolving provider needs and support more personalized treatment planning MALVERN, Pa., May [...]
GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline
14/05/2026
Phase 2a data show zero cough and 60% lower treatment-related diarrhea than placebo despite higher nintedanib use in the active arm – suggesting GRI-0621 may mitigate nintedanib-related GI-toxicities when used in [...]
CapeHaven Completes First Close of Funding and Initiates Operations to Encourage Yale’s Biotech Spinouts
14/05/2026
New Haven-based biotech venture creation platform focused on launching early-stage therapeutics companies from breakthrough Yale University research NEW HAVEN, Conn., May 14, 2026 (GLOBE NEWSWIRE) -- CapeHaven , LLC, a [...]
Biodexa issues letter to Shareholders
14/05/2026
May 14, 2026 Biodexa issues letter to Shareholders Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of [...]
Syneos Health Expands Strategic AI Partnerships to Advance Commercial Precision Performance
14/05/2026
MORRISVILLE, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Syneos Health ® today announced new and expanded strategic partnerships that strengthen its cutting-edge, AI ecosystem. These innovative solutions represent best-in- [...]
Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
14/05/2026
Interim analysis demonstrated a 55.0% relative reduction in proteinuria versus placebo at 39 weeks with eGFR remaining stable through treatment Results further support the potential for telitacicept to become a best-in- [...]
MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Harnesses Key AI, Voice Analysis to Offer Impairment Solution
14/05/2026
Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- MindBio Therapeutics Corp. (CSE: MBIO) ( [...]
Easy Environmental Solutions & Terreplenish® Show Outstanding Yield Increases & Offer Alternative To Petroleum-Based Fertilizers
14/05/2026
Terreplenish® leads the way as company responds to worldwide nitrogen shortage MANKATO, Minn., May 14, 2026 (GLOBE NEWSWIRE) -- Easy Environmental Solutions, Inc. (OTC: EZES) continues to offer a true solution to the [...]
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Responds to BBB Challenge with Next-Gen Drug-Delivery Platform
14/05/2026
NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic [...]
Administrative Experience Emerges as Key Pressure Point for Self-Funded Plans, Brighton Health Plan Solutions Survey Finds
14/05/2026
New report shows employee satisfaction remains high, but trust can break down when administrative friction gets in the way NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- Self-funded health plans are working for many health [...]
Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
14/05/2026
—New C linical and Translational Data Presented at Major Medical Meetings Further Confirms the Disease-Modifying Potential of Nebokitug in Primary Sclerosing Cholangitis and Suggests Possible Additional Benefit in PSC [...]
CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy
14/05/2026
MINNEAPOLIS, May 14, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]
SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Developing Distinct Next-Gen GLP-1 Built Around Novel Peptide
14/05/2026
Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include paid advertising. NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) [...]
Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
14/05/2026
Company plans to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene or CAN-2409) in localized, intermediate- to high-risk prostate cancer in Q4 2026 Announced purpose-built [...]
Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans
14/05/2026
Cena opens up about his experience living with Demodex blepharitis, a common eyelid disease caused by microscopic mites that live in and around the eyelashes This common and often overlooked condition is characterized [...]
Kyverna Therapeutics to Present at Upcoming Investor Conferences
14/05/2026
EMERYVILLE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases [...]
INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease
14/05/2026
BOCA RATON, FL, May 14, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology company focused on inflammation and immunology, today announced that the U.S. Food and Drug Administration (FDA [...]
Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase
14/05/2026
Secured strategic financing vehicle for up to $40 million Positive FDA feedback supports single-arm pivotal trial for potential registration of SENTI-202 in initial indication of Relapsed/Refractory Acute Myeloid [...]

Pages